Kornimate/medical-research-clean huggingface dataset:
monitoring the weight evolution using a connected scale

Conditions: Bariatric Surgery; Long Term Follow-Up; Weight Regain

Summary: current guideline recommend yearly multidisciplinary postoperative follow-up after bariatric surgery. however, practices remain very heterogeneous, and only a fraction of patients are still follow-up beyond two years after the operation. this study will assess a new care pathway in which the patients are follow-up according to the weight evolution measured by the patient using a connected scale.

bariatric surgery is developing rapidly. in france, the number of annual interventions increased threefold between 2001 and 2015, from 16,000 to 50,000 per year. this rapid development is explained by the well-demonstrated benefits of surgery: spectacular improvement in the quality of life, reduction in co-morbidities (diabetes, cardiovascular diseases, and steatohepatitis), and significant reduction in mortality linked to severe obesity. however, the benefits of surgery may decrease over time and may be associated with side effects. current guideline recommend yearly multidisciplinary postoperative follow-up after bariatric surgery. however, practices remain very heterogeneous, and only a fraction of patients are still follow-up beyond two years after the operation. the current recommendations therefore do not seem adapted to clinical reality. they do not prevent the regain of weight in many patients, which frequently leads to re-operations. even more worrying is the possible occurrence of late complications, sometimes serious and life-threatening. this study will assess a new care pathway in which the patients are follow-up according to weight evolution measured by the patient using a connected scale.

Eligibility criteria:
inclusion criteria: patients aged\> = at 18 years old patients who have benefited from a roux-en-y gastric by-pass or sleeve gastrectomy bariatric surgery 2 years ago preoperative body mass index between 35 kg/m2 and 59 kg/m2 access to the wired network at home. social insured patient patient who signed the informed consent exclusion criteria: lack of autonomy for the use of remote monitoring equipment or psychological or psychiatric disorders making it difficult to optimally use the remote monitoring equipment administrative reasons: inability to receive informed consent information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent, patient under guardianship or justice system.
the effect of preoperative anxiety on duration and efficacy of motor and sensory block in spinal anesthesia

Conditions: Anxiety

Summary: spinal anaesthesia results in blockade of sympathetic efferent neurones. patients with higher baseline sympathetic activation have been shown to have more marked hypotension after spinal anaesthesia. anxiety causes generalized sympathetic activation. it was aimed to find the effect of preoperative anxiety on the duration and efficacy of neuraxial anaesthesia.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 55 years. * asa i-ii * bmi 18-25 exclusion criteria: * major surgery
zilver® ptx™ global registry

Conditions: Peripheral Arterial Disease; Peripheral Vascular Disease

Summary: the zilver ptx registry study is a prospective, non-randomized, open-label, multicenter single-arm study enrolling patients in europe, asia, and north america with de novo or restenotic (including in-stent restenosis) lesions of the above-the-knee femoropopliteal artery (sfa). the primary endpoint of the study is event-free survival (efs) at 6 months.


Eligibility criteria:
inclusion criteria: * stenosis of the above-the-knee femoropopliteal artery * appropriate size and location of the lesion exclusion criteria: * pregnant or breast feeding * failure or inability to give informed consent * simultaneously participating in another drug or device study

Keywords: peripheral aterial disease (pad) peripheral vascular disease drug-eluting stent drug-coated stent vascular diseases cardiovascular diseases
quantifying energetic demands of walking for people with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this study is to examine the underlying mechanisms that contribute to high energy costs for people with cerebral palsy (cp) as they walk. the investigators will characterize the cost landscape of children with cp, quantifying the magnitude of cost (net nondimensional oxygen consumption) associated with walking and common sub-tasks of walking, such as supporting and stabilizing the body.

children with cp use large amounts of energy to walk and move, leading to fatigue and limiting participation. for people with cp the energetic cost of walking is on average over two times higher than typically-developing (td) peers. this means that for people with cp, walking is as tiring as jogging or climbing stairs. an energetic cost of this magnitude restricts activities of daily living (adl) and causes exhaustion. while the investigators and many others have sought to reduce these energetic costs through surgical interventions, rehabilitation, orthotics, or other assistive devices, these strategies have failed to result in meaningful reductions in energy. to design strategies that successfully reduce walking costs, the investigators must first understand the underlying mechanisms contributing to elevated cost in people with cp. this basic-science research will provide the foundation to create evidence-based strategies to decrease energy costs, minimize fatigue, and increase quality of life for people with cp and other neurologic injuries.

Eligibility criteria:
inclusion criteria for cases: * 8-17 years old * diagnosed with bilateral cerebral palsy * gross motor function classification system ii * no surgery within the last 9 months * no current baclofen pump or explantation in the last 2 months * no botulinum toxin or phenol injections in the last 2 months * had a prior gait and motion analysis at gillette children's specialty healthcare * participant and caregiver able to speak and read english * ability to follow instructions inclusion criteria for controls: * 8-17 years old * participant and caregiver able to speak and read english * ability to follow instructions

Keywords: energetic cost
pilot study into the use of metformin and ldn for patients with covid-19

Conditions: Covid19

Summary: study into the effects of daily use of metformin and low-dose naltrexone (ldn) for 4 weeks to reduce symptoms, disease severity, and recovery time from covid-19.

the researchers will treat 40 patients with metformin (1500 mg/day) and ldn (4.5 mg/day) for 4 weeks to reduce symptoms, disease severity, and recovery time from covid-19. these 40 patients will be compared with 40 control patients who will receive regular care. all patients will be asked to complete surveys at baseline and after 1, 2, and 4 weeks after initiation of treatment. the difference with baseline at each time point will be assessed. the surveys will assess covid-19 symptoms severity.

Eligibility criteria:
inclusion criteria: * age 30-70 * any sex * any ethnicity * adequate cognitive function to be able to give informed consent * technologically competent to complete web forms and perform video calls with the pi * positive pcr (polymerase chain reaction) test result for sars-cov-2 (severe acute respiratory syndrome coronavirus 2) within the last 10 days * at least two covid-19 symptoms as assessed by laboratory or patient self-reporting started within the last 3 days * willing to fill out regular questionnaires * willing to take metformin and ldn exclusion criteria: * clinically significant hepatic, renal, or cardiac impairment (as determined by previous clinical judgement) * hypoglycemia * currently on drugs for covid-19 * hospitalization for covid-19 * (suspected) pregnancy or breastfeeding * active cancer * uncontrolled mental health issues * on any medication with major interactions with metformin or ldn * taking opioid analgesics, or being treated for opioid addiction/recovery * opioid dependence or withdrawal syndrome * known sensitivity to metformin or naltrexone * current users of metformin or naltrexone

Keywords: metformin ldn low dose naltrexone covid-19
study of mp0112 intravitreal injection in patients with diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to assess the safety and tolerability of mp0112 (a novel, potentially long acting vegf inhibitor) in patients with diabetic retinal edema.


Eligibility criteria:
inclusion criteria: * male or female age 18 years or older * macular edema due to diabetic retinopathy * best-corrected visual acuity in the study eye of 20/40 to 20/400 * central subfield thickness ≥ 250 microns by oct * females of childbearing potential must have a negative serum pregnancy test at screening * male subjects must or be: 1) surgically sterilized for at least 6 months, or 2) use an appropriate method of barrier contraception (e.g., condoms with spermicide) and advise any sexual partner of child-bearing potential that she must also use a reliable method of contraception (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide) during the study and for 30 days from study drug administration. * ability to understand the nature of the study and give written informed consent * willing, committed, and able to return for all clinic visits and complete all study-related procedures exclusion criteria: * any indication of irreversible vision loss such as significant atrophy, scarring, fibrosis, or hyperpigmentation in the fovea * presence of significant ocular abnormalities in the study eye that prevent retinal assessment, including media opacities, cataract, or inadequate papillary dilation * presence of vision loss from another ocular disease other than dme * history of any intraocular surgery within 3 months of baseline * history of intraocular injection of anti-vegf agent or steroids within 3 months of baseline * history of laser photocoagulation for macular edema within 4 months prior to baseline * uncontrolled hypertension \> 140 systolic or \> 95 diastolic * hba1c ≥ 12% * creatinine: \> 1.5 x upper limit of normal (uln) * alanine transaminase (alt), aspartate transaminase (ast), and gamma-glutamyl transferase (ggt): \> uln * white blood cells (wbc), hematocrit, and platelets: \< lower limit of normal (lln) * heart rate \< 60 beats per minute (bpm) or history of clinically significant bradycardia * history of human immunodeficiency virus (hiv), chronic hepatitis b, or chronic hepatitis c infections * subjects with infections requiring hospitalization and/or antibiotic treatment 14 days prior to baseline * subjects with any medical condition that in the judgment of the investigator could poise unacceptable risk to the subject or compromise interpretation of the data to be collected
the combination of ivig, dexamethasone and a megadose of pbscs for decreasing dsas

Conditions: Blood Disease

Summary: donor-specific antibodies (dsas) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-hsct). dsas are unavoidable for some patients who have no alternative donor. effective interventions to reduce dsas are still needed, and the cost of the current therapies is relatively high. investigators wanted to retrospectively analyzed the data of 11 dsa-positive participants who received haplo-hsct at our center and evaluated the therapeutic efficacy of the combination of intravenous immunoglobulin (ivig), dexamethasone and megadose of transfused peripheral blood stem cells (pbscs) for dsa desensitization.

investigators retrospectively analyzed the data of 11 dsa-positive participants who received haplo-hsct at our center. all patients received 1 g/kg ivig on day -1 and 25 mg/m2/d dexamethasone on days -4\~-1 before transplantation, and approximately three doses of pbscs were transfused. on the basis of the conventional transfusion amount of hematopoietic stem cells, additional pbscs were transfused based on the dsa level of each patient: 3±2×108/kg, 6±2×108/kg and 9±2×108/kg mononuclear cells for participants whose dsas were weakly positive, positive and strongly positive, respectively. blood samples from participants were collected at the following 5 time points: before hsct and +1 day, +8 day, +15 day and +22 day after transplantation. the primary endpoint was the incidence of pgf. the secondary endpoints were the incidence of poor graft function, acute and chronic gvhd, relapse, nonrelapse mortality (nrm), overall survival (os) and disease-free survival (dfs).

Eligibility criteria:
inclusion criteria: dsa positive, receive hsct in our hospital. - exclusion criteria: have alternative dsa-negative donor, expended life-span less than 1 month. -
characterization and role of mutations in sodium-phosphate cotransporters in patients with calcific aortic valve disease

Conditions: Aortic Valve Stenosis

Summary: the purpose of this study is to investigate whether mutations in genes coding for na/pi-cotransporters are associated with aortic valve calcification. a patient population with premature aortic valve calcification treated with aortic valve replacement will be screened for mutations in these specific genes. furthermore, aortic valve tissue received from the operations, will be examined for the presence of na/pi-cotransporters, and for molecular characterization of the transporters.


Eligibility criteria:
inclusion criteria: * patients with aortic valve calcification that will be treated with an aortic valve replacement. * age ≤ 65 years. * signed and dated informed consent. exclusion criteria: * inability to provide informed consent * earlier radiation therapy of the thorax * severe renal disease (patients in treatment with dialysis)
comparing autologous blood, corticosteroid, and their combined injection for treating lateral epicondylitis

Conditions: Lateral Epicondylitis; Comparing Autologous Blood Corticosteroid and Their Combined Injection for Treating Lateral Epicondylitis

Summary: the goal of this clinical trial is to compare autologous blood, corticosteroid, and their combined injection for treating lateral epicondylitis. the main question it aims to answer are: • which of these highly used drugs in treatment of lateral epicondylitis is more effective? participants were randomly allocated into three equal treatment groups (ab versus cs versus their combination) with sealed envelopes prepared by a computer-based random number generator. patients in the ab group received 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine hcl, patients in the cs group received 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine hcl, and patients in the combined group (ab+cs) received 1 ml of autologous venous blood, 1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hcl. each group received an equal amount of (3 ml) injected material. prtee and hgs measurements were assessed before the injection (baseline values), on day 15, day 30, and day 90, in the same manner by the senior author.

this study aimed to compare the efficacy of autologous blood (ab) and corticosteroid (cs) injections and their combination in treating lateral epicondylitis (le), hypothesizing that the combined approach might offer immediate symptom resolution and lower recurrence. methods: a total of 120 patients diagnosed with lateral epicondylitis were systematically distributed among three distinct therapeutic injection groups. those in the ab group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine hcl. participants in the cs category were given 1ml of 40 mg methylprednisolone acetate mixed with 2ml of 2% prilocaine hcl. meanwhile, patients in the combined group received a mixture containing 1ml each of autologous venous blood and 40mg methylprednisolone acetate, along with 1ml of 2% prilocaine hcl. prior to receiving their respective injections, a comprehensive assessment of all participants was carried out. follow-up assessments were subsequently conducted on days 15, 30, and 90, utilizing metrics of patient-rated tennis elbow evaluation (prtee) and measurements of hand grip strength (hgs).

Eligibility criteria:
inclusion criteria: 1-patients with le whose complaints persisted for more than 3 months exclusion criteria: 1. patients with a history of recent trauma, 2. congenital or neuromuscular disease or abnormality of the upper limb 3. previous upper limb surgery, 4. history of rheumatic disease, 5. history of cervical disc pathology or carpal tunnel syndrome 6. systemic corticosteroid treatment 7. any previous local injection treatment 8. patients with a history of previous allergic reaction towards local anesthetics and corticosteroids
efficacy and safety of ibi351 in combination with chemotherapy in advanced non-squamous non-small cell lung cancer subjects with kras g12c mutation

Conditions: Advanced Non-Small Cell Lung Cancer

Summary: this phase ib/iii study evaluates the efficacy and safety of ibi351 in combination with chemotherapy in advanced non-squamous nsclc with kras g12c mutation.

this phase ib/iii study evaluates the efficacy and safety of ibi351 in combination with chemotherapy. there will be five cohorts of subjects, all of whom have kras g12c mutation and have advanced or metastatic nsclc. those five cohorts (a, b,c ,d and e) are treated with ibi351, ibi351+sintilimab,ibi351+pemetrexed+cis-platinum/carboplatin,ibi351+cetuximab, or ibi351+pemetrexed+cis-platinum/carboplatin respectively. ibi351 is an orally available small molecule inhibitor of kras g12c.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of nonsquamous nsclc with kras g12c mutation 2. unresectable or metastatic disease 3. adequate organ function 4. not received any systemic antitumor therapy for locally advanced or metastatic non-squamous nsclc previously. exclusion criteria: 1. history of intestinal disease or major gastric surgery or inability to swallow oral medications 2. prior therapy with agents targeting kras g12c mutation (e.g., amg 510). 3. active brain metastases.
the effect of prebiotics on endurance performance

Conditions: Microtia

Summary: the aim of this study is to investigate the effect of a six-week period personalised food intervention with prebiotic supplementation on intense exercise performance in healthy, recreationally active adults.

the study conforms to a randomized, single-blinded, placebo-controlled parallel study design. a prebiotic supplement will be selected based on a participants gut microbiota. 1 sachet of prebiotic or placebo will be given twice a day over a period of 6 weeks. before the start of the study, a vo2max test will be performed. subjects will bring faecal samples which is collected at home. a time to exhaustion of approximately 80% of their vo2max will be performed at baseline and after the 6 weeks intervention period.

Eligibility criteria:
inclusion criteria: * male or female 18 - 40 y * bmi range 18.5 - 25 kg/m2 * recreational active (performing non-competitive physical endurance exercise at least two times per week with a minimum duration of 60 minutes per exercise bout) exclusion criteria: * smoking * performing regular resistance training (3+ times per week, carrying out progressive overload training) * subject following an overly imbalanced or restrictive diet as per nutritional advice * participants who received antibiotics in the 90 days prior to the start of the study * self-admitted lactose intolerance * administration of probiotic or prebiotic supplements in the 14 days prior to the study
a four week study of azithromycin ophthalmic solution, 1% versus placebo in subjects with dry eye disease

Conditions: Dry Eye Disease

Summary: the objective of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% in dry eye subjects over a four week treatment period, using placebo as a comparison.


Eligibility criteria:
inclusion criteria: * have a current diagnosis of dry eye in one or both eyes * moderate to severe degree of meibomian gland plugging * have best corrected visual acuity in both eyes of at least +0.7 logmar * if female, are non-pregnant or non-lactating exclusion criteria: * have anterior blepharitis * have lid structural abnormalities * have suspected ocular fungal or viral infection * have had penetrating intraocular surgery in the past 90 days or require penetrating intraocular surgery during the study * have had ocular surface surgery \[e.g., laser-assisted in situ keratomileusis (lasik), refractive, pterygium\] within the past year. * unable to withhold the use of contact lenses during the study * have a known hypersensitivity to azithromycin, erythromycin, any other macrolide antibiotic, or any of the other ingredients in the study medication. * have a history of post vitreous detachment. * are considered legally blind in 1 eye (logmar bcva= 1.0 or snellen bcva= 20/200). * have permanent conjunctival goblet cell loss or scarring conditions, including cicatricial blepharitis or conjunctivitis. * have a congenitally absent meibomian gland or lacrimal gland. * have had cauterization of the punctum or have had punctal plugs (silicone or collagen) inserted or removed within the 90 days prior to the screening. * have a serious medical condition which would confound study assessments. * have a concomitant ocular pathology that, in the opinion of the investigator, may confound study assessments.